<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989101</url>
  </required_header>
  <id_info>
    <org_study_id>Prevention Nigella 5CH</org_study_id>
    <nct_id>NCT04989101</nct_id>
  </id_info>
  <brief_title>Nigelle 5CH in Prevention of Influanza</brief_title>
  <acronym>Prevention</acronym>
  <official_title>Nigelle 5CH Study Project/ Prevention of Influenza Syndroms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Universitaire Sahloul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Universitaire Sahloul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be carried out by more than 30 liberal Tunisian doctors, who will submit&#xD;
      according to the inclusion / exclusion criteria of people who will receive (free of charge) a&#xD;
      capsule of the Nig5 product sublingually, each day. Against a control group which will be&#xD;
      followed with the same protocol as the first but which will not receive the product.&#xD;
      Randomization (even days: nigella group, odd days: control group)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will focus on the evaluation of the natural product Nigella Sativa in the&#xD;
      fractalized form. &quot;Lactose Nigelle 5&quot; from the Tunisian company Fractal Tun, in terms of&#xD;
      possible contribution to the prevention of influenza-like illnesses, in particular COVID-19&#xD;
&#xD;
      It will be carried out by more than 30 liberal Tunisian doctors, who will submit according to&#xD;
      the inclusion / exclusion criteria of people who will receive (free of charge) a capsule of&#xD;
      the Nig5 product sublingually, each day. Against a control group which will be followed with&#xD;
      the same protocol as the first but which will not receive the product. Randomization (even&#xD;
      days: nigella group, odd days: control group)&#xD;
&#xD;
      The monitoring and evaluation will last for 3 weeks with taking the product Nig5, followed by&#xD;
      a week without taking the product. That is 4 weeks in all.&#xD;
&#xD;
      More than 30 physicians volunteered to participate in this study without remuneration and&#xD;
      without consultation fees for the candidates.&#xD;
&#xD;
      This study will be supervised by Professor Riadh Boukef, head of emergency services at&#xD;
      Sahloul University Hospital, who will collect all the data afterwards in order to submit them&#xD;
      to the statistical tools in force.&#xD;
&#xD;
      Professor Boukef will be responsible for preparing the abstract and publishing it on his&#xD;
      behalf in the scientific journals of his choice, naming the doctors who participated as well&#xD;
      as the product in question and the company that markets it in Tunisia.&#xD;
&#xD;
      27 free practice doctors participate in patient recruitment: AMICHE Sondèss BAHA Mohamed BEN&#xD;
      AMARA Mohamed Khalil BEN ARBIA Karima BEN AYAD Afef BEN AYED KTARI Fouzia BENTALEB Mourad&#xD;
      BESBES Mohamed CHTOUROU Iteb DHOUIB Manel DJAIT Mohamed DJEMAL Najla ELFIDHA Mongi FOURATI&#xD;
      Imen FRIH Sabria FRIKHA Fahmi GHARBI Nadia KAMMOUN Naziha KETATA Mourad MHIRI Ikram NJAH&#xD;
      Jamil OUARGHI Sameh REGAIEG Mourad SAKKA Samar TRABELSI Hinda ZOUARI Imen ZOUARI Nassira&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SarsCOV2 Infection</measure>
    <time_frame>one month</time_frame>
    <description>Respiratory infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contamination</measure>
    <time_frame>one month</time_frame>
    <description>contamination of the entourage in the event of respiratory infection by COVID19</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Nigelle Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up should be done weekly for 1 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nigella</intervention_name>
    <description>The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.</description>
    <arm_group_label>Nigelle Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with an age&gt; 40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being positive for COVID or having contracted it previously&#xD;
&#xD;
          -  Positive for COVID between D1 and D5 of the study, meaning that there was infection&#xD;
             before inclusion.&#xD;
&#xD;
          -  Immunocompromised (HIV, other ...)&#xD;
&#xD;
          -  Under chemotherapy&#xD;
&#xD;
          -  On immunosuppressants&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riadh Boukef, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Sahloul, Sousse, Tunisia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riadh Boukef, professor</last_name>
    <phone>98676745</phone>
    <phone_ext>00216</phone_ext>
    <email>riadboukef@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imen Trabelsi, PhD</last_name>
    <phone>22739092</phone>
    <phone_ext>00216</phone_ext>
    <email>imentrabelsi@hotmail.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HU Sahloul, sousse, Tunisia</name>
      <address>
        <city>Sousse</city>
        <state>Itinéraire Ceinture Cité Sahloul</state>
        <zip>4054</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>boukef riadh, professor</last_name>
      <phone>73 369 411</phone>
      <email>riadboukef@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Universitaire Sahloul</investigator_affiliation>
    <investigator_full_name>Riadh Boukef</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>Nigelle 5CH</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data Statistical analysis</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

